In medical treatment and elsewhere, it has become standard to base treatment intensity (dosage) on evidence in randomized trials. Yet it has been rare to study how outcomes vary with dosage. In trials to obtain drug approval, the norm has been to specify some dose of a new drug and compare it...

While Artificial Intelligence (AI) algorithms have achieved performance levels comparable to human experts on various predictive tasks, human experts can still access valuable contextual information not yet incorporated into AI predictions. Humans assisted by AI predictions could outperform both...

Durch ungeeignete Arzneimitteltherapien und inadäquate Systeminfrastrukturen, die unzureichende Adhärenz, medikationsbedingte Schäden und Medikationsfehler nach sich ziehen, kommen nur allzu oft Patient*innen zu Schaden. Im OECD-Raum ist möglicherweise ein Zehntel der Krankenhauseinweisungen...

We evaluate the introduction of direct-acting antiviral (DAA) therapy for Hepatitis C (HCV) on liver transplant allocation in the United States. We develop a model of listing and organ acceptance behavior for patients with both HCV-positive and HCV-negative end-stage liver disease. In the model,...

We investigate whether increased racial diversity of clinical trial principal investigators could increase the enrollment of Black patients, which currently lags population and disease-burden shares. We conducted a survey experiment in which respondents were shown a photo of a current NIH...

COVID-19 convalescent plasma (CCP) therapy is currently a leading treatment for COVID-19. At present, there is a shortage of CCP relative to demand. We develop and analyze a model of centralized CCP allocation that incorporates both donation and distribution. In order to increase CCP supply, we...